Yeo, Tianrong
Sealey, Megan
Zhou, Yifan
Saldana, Luisa
Loveless, Samantha
Claridge, Timothy D. W.
Robertson, Neil
DeLuca, Gabriele
Palace, Jacqueline
Anthony, Daniel C.
Probert, Fay
Funding for this research was provided by:
National Medical Research Council (NMRC/Fellowship/0038/2016)
Multiple Sclerosis Society
Article History
Received: 26 February 2020
Accepted: 2 July 2020
First Online: 24 July 2020
Competing interests
: TY, MS, YZ, LS, SL, TDWC, GD, DCA, and FP report no disclosures relevant to the manuscript. NR has received honoraria and/or support to attend educational meetings from Biogen, Novartis, Genzyme, Teva, Celgene, and Roche. His institution has also received research support from Biogen, Novartis and Genzyme. JP is partly funded by highly specialised services to run a national congenital myasthenia service and a neuromyelitis service. She has received support for scientific meetings and honorariums for advisory work from Merck Serono, Biogen Idec, Novartis, Teva, Chugai Pharma and Bayer Schering, Alexion, Roche, Genzyme, MedImmune, EuroImmun, MedDay, Abide and ARGENX, and grants from Merck Serono, Novartis, Biogen Idec, Teva, Abide and Bayer Schering. Her hospital trust received funds for her role as clinical lead for the RSS, and she has received grants from the MS society, Guthy Jackson Foundation, NIHR, Oxford Health Services Research Committee, EDEN, MRC and John Fell for research studies.